|
Editor's Note: Select Publications |
Arpino G et al. Estrogen receptor positive (ER+),
progesterone receptor negative (PgR) breast
cancer: New insights into molecular mechanisms
and clinical implications. Breast Cancer Res Treat 2004;Abstract 105.
Bajetta E et al. Safety and efficacy of two
different doses of capecitabine in the treatment
of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-61. Abstract
Baum M, Ravdin PM. Decision-making in early
breast cancer: Guidelines and decision tools. Eur
J Cancer 2002;38(6):745-9. Abstract
Berry DA et al. Effects of improvements in
chemotherapy on disease-free and overall
survival of estrogen-receptor negative, nodepositive
breast cancer: 20-year experience of the
CALGB and US Breast Intergroup. Breast Cancer Res Treat 2004;Abstract 29.
Bertelli G et al. Intergroup exemestane study:
Results of the endometrial subprotocol. Breast Cancer Res Treat 2004;Abstract 402.
Boccardo F et al. Switching to anastrozole
versus continued tamoxifen treatment of early
breast cancer: Preliminary results of the Italian
Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract
Boccardo F et al. Anastrozole appears to be
superior to tamoxifen in women already
receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;Abstract 3.
Citron ML et al. Randomized trial of dosedense
versus conventionally scheduled and
sequential versus concurrent combination
chemotherapy as postoperative adjuvant treatment
of node-positive primary breast cancer:
First report of Intergroup Trial C9741/Cancer
and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Coleman RE et al. Intergroup exemestane study:
1 year results of the bone subprotocol. Breast Cancer Res Treat 2004;Abstract 401.
Coombes RC et al. A randomized trial of
exemestane after two to three years of tamoxifen
therapy in postmenopausal women with primary
breast cancer. N Engl J Med 2004;350(11):1081-
92. Abstract
Cuzick J, Howell A. Optimal timing of the use of
an aromatase inhibitor in the adjuvant treatment
of postmenopausal hormone receptor-positive
breast cancer. Presentation. ASCO
2005;Abstract 658.
Distler W et al. Impact of age on the gynecologic
adverse event (AE) profile of anastrozole
(A) or tamoxifen (T) in the ATAC (‘Arimidex’,
Tamoxifen, Alone or in Combination) trial. Proc ASCO 2004;Abstract 770.
Dowsett M, on behalf of the ATAC Trialists’
Group. Analysis of time to recurrence in the
ATAC (Anastrozole, Tamoxifen, Alone or
in Combination) trial according to estrogen
receptor and progesterone receptor status. Breast Cancer Res Treat 2003;83(Suppl 1):7;Abstract 4.
Duffy S, on behalf of the ATAC Trialist’s
Group. Gynecological adverse events including
hysterectomy occur less frequently with
anastrozole than with tamoxifen: Data from
the ATAC (Arimidex, Tamoxifen, Alone or in
Combination) trial. Proc ASCO 2005;Abstract 723.
Duric V et al. Predictors of the benefits women
consider necessary to make adjuvant chemotherapy
(ACT) worthwhile for early breast
cancer (EBC). Proc ASCO 2004;Abstract 787.
Fallowfield LJ et al. Intergroup exemestane study:
Results of the quality of life sub-protocol. Breast Cancer Res Treat 2004;Abstract 4.
Felson DT, Cummings SR. Aromatase inhibitors
and the syndrome of arthralgias with
estrogen deprivation. Arthritis & Rheumatism 2005;52(9):2594-8. Abstract
Goss PE et al. Randomized trial of letrozole
following tamoxifen as extended adjuvant
therapy in receptor-positive breast cancer:
Updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Goss PE et al. A randomized trial of letrozole
in postmenopausal women after five years of
tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Gradishar WJ et al. Phase III trial of
nanoparticle albumin-bound paclitaxel
compared with polyethylated castor oil-based
paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-7803. Abstract
Henderson IC et al. Improved outcomes from
adding sequential paclitaxel but not from
escalating doxorubicin dose in an adjuvant
chemotherapy regimen for patients with nodepositive
primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract
Hortobagyi GN. Trastuzumab in the
treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. No abstract available
Houghton J et al. Using anastrozole as initial
adjuvant treatment prevents early recurrences
and reduces adverse events: Updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in
Combination) trial. Proc ASCO
2005;Abstract 582.
Howell A et al. Results of the ATAC (Arimidex,
Tamoxifen, Alone or in Combination) trial
after completion of 5 years’ adjuvant treatment
for breast cancer. Lancet 2005;365(9453):60-2.
Abstract
Howell A et al. Comparison of fulvestrant versus
tamoxifen for the treatment of advanced breast
cancer in postmenopausal women previously
untreated with endocrine therapy: A multinational,
double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract
Howell A et al. Fulvestrant, formerly ICI
182,780, is as effective as anastrozole in
postmenopausal women with advanced breast
cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403.
Abstract
Jakesz R et al. Extended adjuvant treatment with
anastrozole: Results from the Austrian Breast
and Colorectal Cancer Study Group Trial 6a
(ABCSG-6a). Proc ASCO 2005;Abstract 527.
Jakesz R et al. Switching of postmenopausal
women with endocrine-responsive early breast
cancer to anastrozole after 2 years’ adjuvant
tamoxifen: Combined results of ABCSG trial 8
and ARNO 95 trial. Lancet 2005;366(9484):455-
62. Abstract
Jakesz R et al. Benefits of switching postmenopausal
women with hormone-sensitive early
breast cancer to anastrozole after 2 years
adjuvant tamoxifen: Combined results from
3,123 women enrolled in the ABCSG Trial 8
and the ARNO 95 Trial. Breast Cancer Res Treat
2004;Abstract 2.
Jones SE et al. Randomized phase III study of
docetaxel compared with paclitaxel in metastatic
breast cancer. J Clin Oncol 2005;23(24):5542-51.
Abstract
Jones SE et al. A retrospective analysis of
the proportion of patients responding for 1,
1.5 and 2 years in two phase III studies of
fulvestrant vs anastrozole. Breast Cancer Res Treat
2004;Abstract 6047.
Locker GY et al. The time course of bone
fractures observed in the ATAC (Arimidex,
Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.
Lonning PE et al. Effects of exemestane administered
for 2 years versus placebo on bone
mineral density, bone biomarkers, and plasma
lipids in patients with surgically resected early
breast cancer. J Clin Oncol 2005;23(22):5126-37.
Abstract
Loprinzi CL, Ravdin PM. Decision-making
for patients with resectable breast cancer:
Individualized decisions for and by patients and
their physicians. JNCCN 2003;1(2):189-96. No abstract available.
Mamounas EP et al. Paclitaxel after doxorubicin
plus cyclophosphamide as adjuvant chemotherapy
for node-positive breast cancer:
Results from NSABP B-28. J Clin Oncol 2005;23(16):3686-96. Abstract
Martin M et al; Breast Cancer International
Research Group 001 Investigators. Adjuvant
docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract
Miller KD et al. E2100: A randomized phase III
trial of paclitaxel versus paclitaxel plus bevacizumab
as first-line therapy for locally recurrent
or metastatic breast cancer. Presentation. Proc ASCO 2005. No abstract available
Miller KD et al. Randomized phase III trial
of capecitabine compared with bevacizumab
plus capecitabine in patients with previously
treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Morales L et al. Acute effects of tamoxifen
and third-generation aromatase inhibitors on
menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15(8):753-60. Abstract
Muss HB et al. Adjuvant chemotherapy in older
and younger women with lymph node-positive
breast cancer. JAMA 2005(9):1073-81. Abstract
Nowak AK et al. Systematic review of taxanecontaining
versus non-taxane-containing
regimens for adjuvant and neoadjuvant treatment
of early breast cancer. Lancet Oncol 2004;5(6):372-80. Abstract
Olivotto IA et al. Population-based validation
of the prognostic model ADJUVANT! for early
breast cancer. J Clin Oncol 2005;23(12):2716-25.
Abstract
Osborne CK et al. Double-blind, randomized
trial comparing the efficacy and tolerability
of fulvestrant versus anastrozole in
postmenopausal women with advanced breast
cancer progressing on prior endocrine therapy:
Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
O’Shaughnessy JA et al. Weekly nanoparticle
albumin paclitaxel (Abraxane) results in
longterm disease control in patients with taxanerefractory
metastatic breast cancer. San Antonio
Breast Cancer Symposium 2004;Abstract 1070.
O’Shaughnessy J et al. Superior survival with
capecitabine plus docetaxel combination therapy
in anthracycline-pretreated patients with
advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Paik S et al. A multigene assay to predict recurrence
of tamoxifen-treated, node-negative breast
cancer. N Engl J Med 2004;351(27):2817-26.
Abstract
Paik S et al. Expression of the 21 genes in the
Recurrence Score assay and prediction of clinical
benefit from tamoxifen in NSABP study B-14
and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 2004;Abstract 24.
Paik S et al. Risk classification of breast cancer
patients by the Recurrence Score assay:
Comparison to guidelines based on patient age,
tumor size, and tumor grade. Breast Cancer Res Treat 2004;Abstract 104.
Peele PB et al. Decreased use of adjuvant breast
cancer therapy in a randomized controlled trial
of a decision aid with individualized risk information. Med Decis Making 2005;25(3):301-7.
Abstract
Perez EA et al. Interim cardiac safety analysis
of NCCTG N9831 Intergroup adjuvant
trastuzumab trial. Proc ASCO
2005;Abstract 556.
Perez EA et al. NCCTG N9831: May 2005
update. Presentation. ASCO 2005;Abstract 556.
Perez EA. Effect of letrozole versus placebo on
bone mineral density in women completing > 5
years (yrs) of adjuvant tamoxifen: NCIC CT
MA17b. Breast Cancer Res Treat
2004;Abstract 404.
Piccart-Gebhart MJ. First results of the HERA
trial. Presentation. ASCO 2005. No abstract
available
Piccart-Gebhart MJ et al. Trastuzumab after
adjuvant chemotherapy in HER2-positive breast
cancer. N Engl J Med 2005;353(16):1659-72.
Abstract
Plourde P et al. Arthralgia in postmenopausal
breast cancer patients on adjuvant endocrine
therapy: A risk-benefit analysis. Poster. Lynn
Sage Breast Cancer Symposium 2005.
Punglia RS et al. Optimizing adjuvant endocrine
therapy in postmenopausal women with earlystage
breast cancer: A decision analysis. J Clin Oncol 2005;23(22):5178-87. Abstract
Ravdin PM et al. Computer program to assist
in making decisions about adjuvant therapy for
women with early breast cancer. J Clin Oncol 2001;19(4):980-91. Abstract
Robertson JF et al. Fulvestrant versus anastrozole
for the treatment of advanced breast carcinoma
in postmenopausal women: A prospective
combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Romond EH et al. Doxorubicin and
cyclophosphamide followed by paclitaxel with
or without trastuzumab as adjuvant therapy for
patients with HER-2 positive operable breast
cancer combined analysis of NSABP-B31/
NCCTG-N9831. Presentation. ASCO 2005. No
abstract available
Romond EH et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive
breast cancer. N Engl J Med 2005;353(16):1673-
84. Abstract
Tan-Chiu E et al. Assessment of cardiac
dysfunction in a randomized trial comparing
doxorubicin and cyclophosphamide followed
by paclitaxel, with or without trastuzumab
as adjuvant therapy in node-positive, human
epidermal growth factor receptor 2-overexpressing
breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
Thürlimann B et al. BIG 1-98: Randomized
double-blind phase III study to evaluate
letrozole (L) vs tamoxifen (T) as adjuvant
endocrine therapy for postmenopausal women
with receptor-positive breast cancer. Proc ASCO
2005;Abstract 511.
Wasan KM et al. The influence of letrozole on
serum lipid concentrations in postmenopausal
women with primary breast cancer who have
completed 5 years of adjuvant tamoxifen (NCIC
CTG MA.17L). Ann Oncol 2005;16(5):707-15.
Abstract
Winer EP et al. American Society of Clinical
Oncology technology assessment on the use of
aromatase inhibitors as adjuvant therapy for
postmenopausal women with hormone receptorpositive
breast cancer: Status report 2004. J Clin Oncol 2005;23(3):619-29. Abstract
|